MEK1/2 inhibitor sensitizes pre-B ALL primary blasts to glucocorticoid treatment through a mechanism involving modulation of mTOR activity and induction of LC3 processing. The gene discussed is MAP1LC3A; the disease is acute lymphoblastic leukemia.